News & Updates
Filter by Specialty:
Neoadjuvant cycles do not alter perioperative nivolumab benefit in resectable NSCLC
Treatment with nivolumab plus chemotherapy before surgery followed by nivolumab after surgery yields superior outcomes for patients with resectable nonsmall cell lung cancer (NSCLC) as compared with placebo plus chemotherapy, regardless of the number of completed neoadjuvant cycles, according to an exploratory analysis of the CHECKMATE 77T trial.
Neoadjuvant cycles do not alter perioperative nivolumab benefit in resectable NSCLC
02 Jul 2024
Subcutaneous atezolizumab favoured over intravenous infusion
Nonsmall cell lung cancer (NSCLC) patients with high PD-L1 expression appear to show a strong preference for receiving atezolizumab subcutaneously rather than intravenously.
Subcutaneous atezolizumab favoured over intravenous infusion
02 Jul 2024
Increasing trend in DOAC-related intracerebral haemorrhage: How to improve outcomes?
New local findings presented at HKMF 2024 show an increasing trend in intracerebral haemorrhage (ICH) among patients on direct oral anticoagulants (DOACs) between 2013 and 2022. Early initiation of reversal agents may improve outcomes in select cases with DOAC-related ICH.